Balveen Kaur

14PUBLICATIONS
52CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Autonomic nervous systemMedical biochemistry - amino acids and metabolitesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 12, 2026
Development and preclinical evaluation of a decoy DLL4-encoding oncolytic HSV-1 for high-grade glioma.

|Aug 14, 2026
Potential for enhanced oncolytic HSV-1 therapy via SHED as a vehicle against malignant gliomas.

|Jan 08, 2026
CD73 blockade enhances antitumor efficacy of oHSV in solid tumors by increasing macrophage-mediated antigen presentation.

Sara A Murphy, Jiaqi Li, Upasana Sahu

|Dec 18, 2025
Oncolytic HSV-1-Mediated JAG1 Blockade Induces Glioma Senescence-Associated Secretory Phenotype to Increase Macrophage Activation and Cetuximab-Mediated Senolysis.

Kimberly A Rivera-Caraballo, Tae Jin Lee, Arnoneel Sinha

|Apr 24, 2025
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity.

Upasana Sahu, Matthew P Mullarkey, Sara A Murphy

|Apr 05, 2025
β-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy.

Konstantina Kyritsi, Rafal Pacholczyk, Eugene Douglass

Pageof 3

Frequent Collaborators

3 joint publications

Kimberly Rivera-Caraballo

3 joint publications

Bangxing Hong

3 joint publications

Zhongming Zhao

2 joint publications

Sara A Murphy